Dapagliflozin confers more favorable cardiometabolic outcomes vs. vildagliptin

This study aimed to compare the cardiometabolic effects of dapagliflozin and vildagliptin in type 2 diabetes patients with coronary artery disease. Researchers conducted a randomized, double-blind, single-center study in which 43 patients with type 2 dia https://www.healio.com/cardiology/diabetes/news/online/%7B22c6a305-8e42-4fc9-9187-a9c2d132362f%7D/dapagliflozin-confers-more-favorable-cardiometabolic-outcomes-vs-vildagliptin